16 September 2019
The head of Russia’s Ministry of Health, Veronika Skvortsova, announced the start of vaccination with a new quadrivalent influenza vaccine of high-risk groups, and by 2023 the Ministry plans to completely replace the existing trivalent vaccines. According to Skvortsova, the peculiarity of the new vaccine is that it forms the immunity against two influenza A virus strains (H1N1 and H3N2) and two influenza B virus strains (Victoria and Yamagata).
Traditionally, influenza virus В has been perceived as less virulent and incapable of causing large-scale epidemics and severe diseases. However, based on recent experience, the footprint of influenza В broadens, and its contribution to seasonal epidemics increases. In 2012, based on the results of many-year monitoring, the WHO recognized the potential benefits of including second strain B into trivalent vaccines, and as soon as in 2013, the first quadrivalent influenza vaccine was approved in Europe.
In July 2018, Petrovax Pharm received Marketing Authorization No. LP-004951 for Grippol® Quadrivalent, a 4-valent inactivated subunit adjuvanted vaccine designed for prevention of influenza. It is the most advanced flu vaccine in the world that employs an antigen sparing technology and has a high preventive activity and safety.
Grippol® Quadrivalent is manufactured in Russia full-cycle starting from API production to the applicable GMP regulations. The vaccine is preservative-free and released in single-dose syringes. The key benefit of the Russian quadrivalent vaccine is a high efficacy with low reactogenicity.
Only six countries manufacture quadrivalent vaccines on their own, including Australia, the USA, Canada, New Zealand, Germany, and France. Russia is the 7th country that has independent vaccine production capacities.Print
09 July 2020
08 July 2020
08 July 2020
07 July 2020